FAM102B Inhibitors
FAM102B inhibitors encompass a diverse range of chemical compounds that suppress the functional activity of FAM102B through their influence on various cellular signaling pathways. MEK inhibitors such as U0126 and PD 98059 work by halting the ERK/MAPK signaling cascade, which is crucial for the regulation and function of proteins like FAM102B; by blocking MEK, these inhibitors prevent the phosphorylation and subsequent activation of ERK, leading to a reduction in FAM102B activity. Similarly, PI3K inhibitors, LY 294002 and Wortmannin, decrease the production of PIP3 and consequently inhibit AKT activation, likely affecting FAM102B if it is tiedto this pathway. Inhibition of mTOR by compounds like Rapamycin and Torin 1 hinders cell growth and proliferation pathways, which can reduce the protein synthesis required for FAM102B's functional activity. On another front, Thapsigargin disrupts calcium homeostasis by targeting the SERCA pump, which could impact FAM102B if it is involved in calcium signaling, while SB 203580 and SP600125 target the stress-activated MAPK pathways, p38, and JNK, respectively, potentially diminishing FAM102B's activity related to stress responses.
Additionally, Cyclopamine's inhibition of the Hedgehog signaling pathway and Bafilomycin A1's disruption of vacuolar acidification both offer indirect routes to suppress FAM102B by affecting pathways that FAM102B may be associated with. The glycolysis inhibitor 2-Deoxy-D-glucose imposes an energy constraint, which could lead to a reduction in FAM102B activity if it relies on glycolytic ATP for its function. Collectively, though these inhibitors act on different aspects of cellular function, their convergence on the inhibition of FAM102B illustrates the complex interplay of signaling pathways that regulate the activity of this protein. Each inhibitor's specific biochemical mechanism contributes to a cumulative decrease in FAM102B's functionality, underlining the integrated nature of cellular signaling to achieve a targeted inhibitory effect on FAM102B.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A MEK inhibitor that indirectly diminishes the activity of FAM102B by disrupting the ERK/MAPK signaling pathway, which FAM102B may be associated with. By inhibiting MEK, U0126 prevents the phosphorylation and activation of ERK, which in turn could reduce the downstream effects on proteins like FAM102B that are modulated by this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that indirectly leads to the inhibition of FAM102B by altering the AKT signaling cascade. LY 294002 blocks the formation of PIP3, which is necessary for AKT activation. Reduced AKT activity may negatively impact the functional activity of FAM102B if it is involved in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can indirectly inhibit FAM102B by impeding the mTOR pathway, which is involved in cell growth and proliferation. Inhibition of mTOR can lead to a decrease in the protein synthesis machinery that might be necessary for the functional activity of FAM102B. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A SERCA pump inhibitor that indirectly inhibits FAM102B function by perturbing calcium homeostasis within the endoplasmic reticulum, potentially affecting proteins associated with calcium signaling, such as FAM102B. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that indirectly diminishes the activity of FAM102B by inhibiting the p38 MAPK signaling pathway, which could influence proteins regulated by stress-activated protein kinase pathways, including FAM102B. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that indirectly inhibits FAM102B by disrupting AKT signaling and potentially affecting proteins regulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that indirectly inhibits FAM102B by blocking the ERK/MAPK signaling pathway. PD 98059 prevents MEK from activating ERK, which in turn may reduce the functional activity of proteins like FAM102B that are potentially regulated by this pathway. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
A Hedgehog signaling pathway inhibitor that indirectly inhibits FAM102B by blocking Smoothened, a G protein-coupled receptor. This action diminishes the pathway's signaling, potentially affecting proteins, like FAM102B, associated with this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that indirectly inhibits FAM102B by impeding the JNK signaling pathway, which may influence proteins involved in stress response, including FAM102B. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A vacuolar H+-ATPase inhibitor that indirectly inhibits FAM102B by disrupting endosomal-lysosomal acidification, which in turn can affect the function of proteins, like FAM102B, that are dependent on this process. | ||||||